Lamictal (Epilepsy)：市場予測と分析（～2022）...市場調査レポートについてご紹介

1 Table of Contents
1 Table of Contents 5
1.1 List of Tables 7
1.2 List of Figures 7
2 Introduction 8
2.1 Catalyst 8
2.2 Related Reports 9
3 Disease Overview 11
3.1 Classification of Seizures 13
3.2 Etiology and Pathophysiology 14
3.2.1 Etiology 14
3.2.2 Pathophysiology 17
3.2.3 Prognosis 22
3.2.4 Quality of Life 23
4 Disease Management 24
4.1 Diagnosis 24
4.2 Treatment Guidelines 25
4.3 Clinical Practice 26
5 Competitive Assessment 32
5.1 Overview 32
5.2 Strategic Competitor Assessment 34
6 Lamictal (lamotrigine) 37
6.1 Overview 37
6.2 Therapeutic Role 38
6.3 Efficacy 38
6.3.1 Epilepsy – Monotherapy With Lamictal in Adults with Partial Seizures Already Receiving Treatment with Carbamazepine, Phenytoin, Phenobarbital, or Primidone as the Single AED 38
6.3.2 Adjunctive Therapy with Lamictal in Adults with Partial Seizures 39
6.3.3 Adjunctive Therapy with Lamictal in Pediatric Patients with Partial Seizures 39
6.3.4 Adjunctive Therapy with Lamictal in Pediatric and Adult Patients with Primary Generalized Tonic-Clonic Seizures 39
6.4 Safety 40
6.5 SWOT Analysis 41
6.6 Forecast 41
7 Appendix 43
7.1 Bibliography 43
7.2 Abbreviations 45
7.3 Methodology 47
7.4 Forecasting Methodology 47
7.4.1 Prevalent Epilepsy Patients 47
7.4.2 Percent Drug-Treated Patients 48
7.4.3 General Pricing Assumptions 48
7.4.4 Individual Drug Assumptions 49
7.4.5 Generic Erosion 50
7.5 Physicians and Specialists Included in this Study 50
7.6 Primary Research – Prescriber Survey 51
7.7 About the Authors 51
7.7.1 Authors 51
7.7.2 Global Head of Healthcare 52
7.8 About GlobalData 53
7.9 Contact Us 53
7.10 Disclaimer 53